| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 02/28/2013 | US20130052259 Liposomes comprising amphipathic drugs and method for their preparation |
| 02/28/2013 | US20130052258 Polypeptides and uses thereof |
| 02/28/2013 | US20130052256 Nail discoloration and fungus treatment |
| 02/28/2013 | US20130052255 Nail discoloration and fungus treatment |
| 02/28/2013 | US20130052254 System and method for a piezoelectric scaffold for tissue growth and repair |
| 02/28/2013 | US20130052253 Flavoring of drug-containing chewing gums |
| 02/28/2013 | US20130052252 Hard Coated Confectionary Having A Consumable Soft Chewing Core With A Heat Sensitive Particulate Active And Method For Making Same |
| 02/28/2013 | US20130052251 Composition and method for treating nosebleeds |
| 02/28/2013 | US20130052250 Compounds and methods for biofilm disruption and prevention |
| 02/28/2013 | US20130052249 Antimicrobial composition |
| 02/28/2013 | US20130052248 Item of clothing for daily pharmacological treatment of a fungal infection |
| 02/28/2013 | US20130052245 Cosmetic and dermatological formulations of mntf peptides |
| 02/28/2013 | US20130052241 Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
| 02/28/2013 | US20130052240 Dermal micro-organs, methods and apparatuses for producing and using the same |
| 02/28/2013 | US20130052239 Formulation |
| 02/28/2013 | US20130052238 Gene delivery of oct4 and sirt1 and pharmaceutical compositions thereof |
| 02/28/2013 | US20130052237 Methods of Manufacturing Viscous Liquid Pharmaceutical Formulations |
| 02/28/2013 | US20130052236 Composite polylactic acid/alginate surgical barrier |
| 02/28/2013 | US20130052235 Herpes simplex virus nanoemulsion vaccine |
| 02/28/2013 | US20130052234 Edible strips |
| 02/28/2013 | US20130052233 Dry Powder Pharmaceutical Compositions, Its Preparation Process and Stable Aqueous Suspension Obtained from such Composition |
| 02/28/2013 | US20130052232 Method for the preparation of a heat stable oxygen carrier-containing composition facilating beta-beta cross-linking |
| 02/28/2013 | US20130052142 Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
| 02/28/2013 | US20130052134 Peg-plga-pll polymer and method for preparing and using the same as the drug and gene carrier |
| 02/28/2013 | US20130052127 Composite body for antigen or drug delivery |
| 02/28/2013 | DE4396086B3 Sirup mit N-Acetylcystein Syrup with N-acetylcysteine |
| 02/28/2013 | DE102011111248A1 Capsule, useful e.g. to treat intestinal tract, comprises an outer shell with two opposite openings, which is dissolved by the digestive secretions of the intestinal tract after a predetermined time and contains a contrast agent |
| 02/28/2013 | DE102011053068A1 Darreichungsform mit stabilisierten Wirkstoffpartikeln Dosage form stabilized drug particles |
| 02/28/2013 | CA2846121A1 Hydrous adhesive skin patch |
| 02/28/2013 | CA2845691A1 Liposome comprising at least one cholesterol derivative |
| 02/28/2013 | CA2845275A1 Ophthalmic formulations |
| 02/28/2013 | CA2845258A1 Method for preparing metered dose sprayed inhaler for treating respiratory disease |
| 02/28/2013 | CA2845175A1 Method for preparing an aromatic composition including a compound containing two solids having organoleptic properties |
| 02/28/2013 | CA2842177A1 Formulations of deoxycholic acid and salts thereof |
| 02/27/2013 | EP2561892A1 Easily dosable solid preparation |
| 02/27/2013 | EP2561878A1 Calcium preparation and production method therefor |
| 02/27/2013 | EP2561877A1 A Composition containing a Bisphosphonic Acid in combination with Vitamin D |
| 02/27/2013 | EP2561865A2 Transdermal absorption preparation |
| 02/27/2013 | EP2561864A1 Coated tablet comprising tianeptine and process for preparation thereof |
| 02/27/2013 | EP2561863A1 Pharmaceutical compositions comprising voriconazole |
| 02/27/2013 | EP2561862A1 Vesicle-containing composition |
| 02/27/2013 | EP2561861A1 Water-soluble pharmaceutical composition comprising at least one therapeutically active substance having hydrophobic properties and at least one compound selected from among sialoglycosphingolipids, glycosphingolipids or a mixture of sialoglycosphingolipids and glycosphingolipids |
| 02/27/2013 | EP2561860A1 Implantable polymeric device for sustained release of buprenorphine |
| 02/27/2013 | EP2561829A1 Tool for transferring membranous tissue, kit and method for transferring membranous tissue |
| 02/27/2013 | EP2560752A1 Capsule comprising active ingredient |
| 02/27/2013 | EP2560732A2 A solid pharmaceutical composition for neutralizing stomach acid |
| 02/27/2013 | EP2560691A2 Process for preparing an immunoglobulin composition |
| 02/27/2013 | EP2560682A2 Antibody preparations |
| 02/27/2013 | EP2560674A2 Nanoparticle targeting to ischemia for imaging and therapy |
| 02/27/2013 | EP2560666A1 Active ingredient combinations of magnolia bark extract and surface-active agents (polyglyceryl-3 methylglucose distearate) |
| 02/27/2013 | EP2560665A1 Cosmetic or dermatological preparations comprising combinations of magnolia bark extract and alkyl sulphates |
| 02/27/2013 | EP2560663A1 Methods and compositions for reducing or preventing vascular calcification during peritoneal dialysis therapy |
| 02/27/2013 | EP2560633A2 Intravenous omega-3 fatty acid compositions & method of use |
| 02/27/2013 | EP2560630A2 Tuberculosis drug based on 4-thioureido-iminomethylpyridinium perchlorate: method of preparation and treatment |
| 02/27/2013 | EP2560626A1 Local anesthetic emulsion compositions and methods of making and using the same |
| 02/27/2013 | EP2560625A2 Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same |
| 02/27/2013 | EP2560624A1 Therapeutic formulation for reduced drug side effects |
| 02/27/2013 | EP2560623A1 Oral sustained release formulation of huperzine a |
| 02/27/2013 | EP2560622A1 Pramipexole-containing matrix tablet |
| 02/27/2013 | EP2560621A1 Fingolimod in the form of a solid solution |
| 02/27/2013 | EP2560620A2 A process for particle processing of active pharmaceutical ingredients |
| 02/27/2013 | EP2560619A2 A method of preparing an oral dosage form comprising fingolimod |
| 02/27/2013 | EP2560618A1 Melt-granulated fingolimod |
| 02/27/2013 | EP2560617A2 Pharmaceutical compositions |
| 02/27/2013 | EP2560616A2 Artificial tear emulsion |
| 02/27/2013 | EP2560615A1 Thiazolidinedione analogues |
| 02/27/2013 | EP2560614A1 Pharmaceutical compositions and methods for administering the same |
| 02/27/2013 | EP2560613A2 Fexofenadine-based composition and preparation process therefor |
| 02/27/2013 | EP2560612A1 Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same |
| 02/27/2013 | EP2560611A1 "process for providing particles with reduced electrostatic charges" |
| 02/27/2013 | EP2560610A1 Taste masked dosage form of pharmaceutically acceptable salt of escitalopram |
| 02/27/2013 | EP2560605A1 Active ingredient combinations of magnolia bark extract and polyethoxylated compounds (peg-40 stearates) |
| 02/27/2013 | EP2560484A1 A pharmaceutical composition of nanoparticles |
| 02/27/2013 | EP2545940A9 Parenteral compositions |
| 02/27/2013 | CN202751611U Diffused particle for treating esophagus cancer |
| 02/27/2013 | CN202751610U Diffused particle for treating diabetes |
| 02/27/2013 | CN102946889A Calcium preparation and production method therefor |
| 02/27/2013 | CN102946886A 透析前体组合物 Dialysis precursor composition |
| 02/27/2013 | CN102946883A Method and ophthalmic composition for treating retinal disease |
| 02/27/2013 | CN102946873A Transdermal absorption preparation |
| 02/27/2013 | CN102946872A Micropellet compositions comprising pancreatin containing digestive enzyme mixtures |
| 02/27/2013 | CN102946871A Pharmaceutical compositions of co-crystals of tramadol and coxibs |
| 02/27/2013 | CN102946870A Pharmaceutical compositions comprising hydromorphone and naloxone |
| 02/27/2013 | CN102946869A Immediate release formulations and dosage forms of gamma-hydroxybutyrate |
| 02/27/2013 | CN102946868A Dry powder formulation comprising an antimuscarinic drug |
| 02/27/2013 | CN102946867A Compoisitons comprising polyglutamic acid nanoparticles and polypeptides such as cd40 agonists |
| 02/27/2013 | CN102946866A Food compositions comprising organogels |
| 02/27/2013 | CN102946865A Low-oil pharmaceutical emulsion compositions comprising progestogen |
| 02/27/2013 | CN102946864A Pharmaceutical emulsion compositions comprising progestogen |
| 02/27/2013 | CN102946863A Long-term storage of non-glycosylated recombinant human G-CSF |
| 02/27/2013 | CN102946862A Topical pharmaceutical composition comprising heparin |
| 02/27/2013 | CN102946861A Concentrated protein formulations and uses thereof |
| 02/27/2013 | CN102946860A 噻唑烷二酮类似物 Thiazolidinedione analogs |
| 02/27/2013 | CN102946859A Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| 02/27/2013 | CN102946858A Liquid formulation of polypeptides containing an Fc domain of an immunoglobulin |
| 02/27/2013 | CN102946857A Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same |
| 02/27/2013 | CN102946856A Oral film formulation |
| 02/27/2013 | CN102946855A Topical ophthalmic suspensions containing tobramycin and dexamethasone |
| 02/27/2013 | CN102946846A Antiperspirant composition |
| 02/27/2013 | CN102946841A Therapeutic oral composition |